Ellsworth Advisors LLC Invests $650,000 in ANI Pharmaceuticals, Inc. $ANIP

Ellsworth Advisors LLC bought a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the fourth quarter, Holdings Channel.com reports. The fund bought 7,619 shares of the specialty pharmaceutical company’s stock, valued at approximately $650,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. Advisors Asset Management Inc. purchased a new position in ANI Pharmaceuticals in the first quarter worth approximately $28,000. Hantz Financial Services Inc. grew its holdings in ANI Pharmaceuticals by 202.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after acquiring an additional 237 shares in the last quarter. Newbridge Financial Services Group Inc. increased its position in shares of ANI Pharmaceuticals by 200.0% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after purchasing an additional 400 shares during the last quarter. State of Wyoming acquired a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at $50,000. Finally, CWM LLC raised its holdings in shares of ANI Pharmaceuticals by 159.1% in the 3rd quarter. CWM LLC now owns 798 shares of the specialty pharmaceutical company’s stock valued at $73,000 after purchasing an additional 490 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $74.21 on Friday. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.71 and a quick ratio of 2.19. ANI Pharmaceuticals, Inc. has a 1 year low of $56.71 and a 1 year high of $99.50. The company has a market capitalization of $1.66 billion, a PE ratio of 22.09 and a beta of 0.44. The company has a fifty day moving average of $76.78 and a two-hundred day moving average of $83.32.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ANIP shares. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 14th. Barclays initiated coverage on ANI Pharmaceuticals in a report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price target for the company. Guggenheim upped their price objective on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Five research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $107.33.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, SVP Thomas Andrew Rowland sold 4,772 shares of the firm’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $74.91, for a total transaction of $357,470.52. Following the transaction, the senior vice president owned 38,730 shares in the company, valued at $2,901,264.30. This trade represents a 10.97% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Stephen P. Carey sold 7,312 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $75.50, for a total value of $552,056.00. Following the transaction, the chief financial officer directly owned 185,543 shares in the company, valued at approximately $14,008,496.50. This trade represents a 3.79% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 27,860 shares of company stock valued at $2,114,771. 11.10% of the stock is owned by insiders.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.